Please login to the form below
SOBI
This page shows the latest SOBI news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca blocks take-private buyout of Sobi
While the deal was approved by the Sobi board, it was conditional on 90% of shareholders agreeing. ... We have a strong belief in Sobi’s strategy and the opportunities ahead.
Latest news
-
EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
patients. This is EMA’s latest review of a potential coronavirus treatment, following announcements that it is evaluating an arthritis drug developed by Sweden’s Sobi to treat COVID-19 in
-
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
Sobi requested that the CHMP re-examine the application for Gamifant (emapalumab) as a treatment for of primary haemophagocytic lymphohistiocytosis (HLH) after the Committee initially rejected the drug in July. ... In the US, over 100 primary HLH
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
Sobi has said it plans to request a re-examination by the CHMP and expects a subsequent opinion by the end of the year. ... The product has been able to make a substantial difference for a very vulnerable group of patients in the US,” said Guido Oelkers
-
Sobi set to spend up to $915m to acquire Dova Pharmaceuticals
Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval ... Under the terms of the agreement, Sobi will offer a
-
FDA approves Bavarian Nordic’s smallpox and monkeypox vaccine
Earlier this year, AstraZeneca picked up a PRV from Sobi for $95m.
More from news
Approximately 13 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Heggie has lots of experience in the rare disease field, having served in senior roles at Shire, as a board member at Sobi and as CEO of German rare disease biotech
-
A rare opportunity
Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing. ... An exciting time. For Neil's company Sobi it's certainly been a busy time this year.
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
Most recently, Levin worked as the president of Sobi, where he was responsible for building the organisation and developing the strategic growth pillars of the company. ... Prior to Sobi, Levin held commercial leadership roles of increasing strategic
-
BMS appoints new commercial leader, Davies joins Eisai and more
Sobi appoints head of technical operations. Rare disease specialist company Sobi has appointed Anne Marie de Jonge Schuermans to front its new technical operations organisation. ... operations. She joins Sobi from Biogen, where she served as vice
-
Sobi poaches Pfizer’s Fredrick Wetterlundh
Swedish Orphan Biovitrum (Sobi) has appointed Fredrik Wetterlundh as head of human resources and will simultaneously be part of Sobi’s extended leadership team. ... Guido Oelkers, CEO and president of Sobi, said: “His experience from the
-
Mereo BioPharma appoints head of patient access and commercial planning
Wills Hughes-Wilson joins the group from Sobi. London, UK-based Mereo BioPharma, has strengthened its team with the addition of Wills Hughes-Wilson, who joins the biopharma as its new ... In this role, Hughes-Wilson was responsible for Sobi’s
-
Sobi names Holly May VP of sales and marketing, US
Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US. ... May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country.
More from appointments
Approximately 9 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
The RARE Youth Revolution has begun
LifeArc. Sobi. “We are a proud supporter of RARE Youth Revolution and we are absolutely thrilled to have them as part of the Breaking Down Barriers project!
-
IGNIFI
Kyowa Kirin. Sobi. Theramex. Veriton Pharma. Vifor Pharma.
-
Say Communications
Novo Nordisk. Nutricia. Nutricia Global. SOBI. Target Ovarian Cancer. Trudell Medical.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
